The Montreal Cognitive Assessment (MoCA) as a cognitive screen in addiction health care: A validation study for clinical practice
Autor: | C.A.J. de Jong, C.J.W.H. Bruijnen, S. Lugtmeijer, M. Jansen, Wiebren Markus, Boukje A G Dijkstra, Roy P. C. Kessels, S.J.W. Walvoort |
---|---|
Rok vydání: | 2019 |
Předmět: |
Validation study
Alzheimer`s disease Donders Center for Medical Neuroscience [Radboudumc 1] Health (social science) media_common.quotation_subject 030508 substance abuse Medicine (miscellaneous) Experimental Psychopathology and Treatment 03 medical and health sciences All institutes and research themes of the Radboud University Medical Center 0302 clinical medicine Health care Criterion validity medicine 030212 general & internal medicine media_common Neuro- en revalidatiepsychologie business.industry Addiction Neuropsychology and rehabilitation psychology Montreal Cognitive Assessment Cognition Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] medicine.disease Clinical Practice Substance abuse 0305 other medical science business Psychology Clinical psychology |
Zdroj: | Journal of Substance Use, 24, 1, pp. 47-54 Journal of Substance Use, 24, 47-54 |
ISSN: | 1465-9891 |
Popis: | Contains fulltext : 197451.pdf (Publisher’s version ) (Open Access) Objective: The current study assessed the criterion validity of the Montreal Cognitive Assessment (MoCA) as a short cognitive screen for use in addiction health care. Method: Eighty-two patients were assessed with two parallel versions of the MoCA; at intake (baseline) and directly preceding an extensive neuropsychological assessment (NPA) approximately 8 weeks later (follow-up). Results: Of all included patients, 54.9% were classified as having substance-induced neurocognitive disorder. The most common primary substance of abuse was alcohol (70.7%). The criterion validity was determined predictively and concurrently, and sensitivities of .56 and .67 and specificities of .62 and .73 were found, respectively. Conclusion: While the MoCA is an adequate screen when administered at the same time as the NPA, the predictive validity of administering this cognitive screen at intake is limited. Furthermore, the relation between MoCA domain scores and the performance on their corresponding cognitive domain in the NPA is more reliable when the MoCA is administered at the same time as the NPA. While the MoCA can be used to screen for cognitive impairments in patients in addiction health care, the instrument?s sensitivity is not optimal, which should be taken into account when interpreting results. 8 p. |
Databáze: | OpenAIRE |
Externí odkaz: |